Treatment with Intensity-Modulated Radiation Therapy (IMRT) and Chemotherapy in Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC): Toxicity, Survival and Patterns of Failure in Relation to Treatment with High and Low Radiation Dose — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Treatment with Intensity-Modulated Radiation Therapy (IMRT) and Chemotherapy in Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC): Toxicity, Survival and Patterns of Failure in Relation to Treatment with High and Low Radiation Dose
Bismarck Cancer Center, Bismarck, ND, USA
,
Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, USA
,
Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA
,
Department of Therapeutic Radiation, Yale School of Medicine, New Haven, CT, USA
,
Bismarck Cancer Center, Bismarck, ND, USA
,
Department of Medical Oncology, Sanford Health, Bismarck, ND, USA
,
Department of Medical Oncology, St. Alexius Health, Bismarck, ND, USA
,
Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, USA
1 Bismarck Cancer Center, Bismarck, ND, USA
2 Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, USA
3 Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA
4 Department of Therapeutic Radiation, Yale School of Medicine, New Haven, CT, USA
5 Bismarck Cancer Center, Bismarck, ND, USA
6 Department of Medical Oncology, Sanford Health, Bismarck, ND, USA
7 Department of Medical Oncology, St. Alexius Health, Bismarck, ND, USA
8 Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, USA
Purpose: To investigate the toxicity, survival and patterns of failure in patients with advanced lung cancer treated with intensity modulated radiation therapy (IMRT) and chemotherapy. Methods and Materials: Retrospective chart review of 68 total patients: 46 academic and 22 community center. Endpoints: Grade ≥ 3 pneumonitis, Grade ≥ 2 esophagitis, local, regional and distant failure, progression-free survival (PFS) and overall survival (OS). Results: For the academic center patients, median follow-up was 19.2 months. Esophagitis: 0% Grade 3, 35% Grade 2, no significant difference between dose bins: <70 Gy vs. 70 Gy, 25% vs. 45% (p = 0.22), <66 Gy vs. 66 - 70 Gy, 28% vs. 39% (p = 0.53). Lung dose metrics and PTV size were not associated with Grade ≥ 3 pneumonitis. Esophageal V35, V50, and mean dose but not PTV size was associated with Grade 2 esophagitis. 1 year local, regional and distant failure = 6.5%, 6.5%, and 30.4%. No endpoint differences were seen between dose bins, though patients with smaller PTVs treated with 70 Gy did demonstrate improved OS (ns) when compared to those treated with <70 Gy. Community Center: Median follow-up 6.2 months with 15% Grade 2 esophagitis, no Grade 3 esophagitis. Two patients (9%) experienced Grade ≥ 3 pneumonitis. Conclusions: IMRT chemoradiation was well tolerated in a population with advanced NSCLC both in the academic and community settings. Severe pneumonitis rates were low and comparable to other series using IMRT and chemotherapy. Esophagitis was mild and associated with V35, V50 and mean dose. No significant benefit was seen for higher doses regarding survival, local, regional or distant control despite that higher dose bins had smaller tumors. Though not statistically significant, we did find a trend toward worse OS for <70 Gy when the PTV was less than the median PTV.
KeywordsIMRTNSCLCToxicitySurvivalPatterns of FailureChemotherapy
Siegel, R., Naishadham, D. and Jemal, A. (2013) Cancer Statistics. CA: A Cancer Journal for Clinicians, 63, 11-30. http://dx.doi.org/10.3322/caac.21166
Ramnath, N., Dilling, T.J., Harris, L.J., et al. (2013) Treatment of Stage III Non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 143, e314S-e340S.
Rengan, R., Rosenzweig, K.E., Venkatraman, E., et al. (2004) Improved Local Control with Higher Doses of Radiation in Large-Volume Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 60, 741-747. http://dx.doi.org/10.1016/j.ijrobp.2004.04.013
Grills, I.S., Yan, D., Martinez, A.A., et al. (2003) Potential for Reduced Toxicity and dose Escalation in the Treatment of Inoperable Non-Small-Cell Lung Cancer: A Comparison of Intensity-Modulated Radiation Therapy (IMRT), 3D Conformal Radiation, and Elective Nodal Irradiation. International Journal of Radiation Oncology, Biology, Physics, 57, 875-890. http://dx.doi.org/10.1016/S0360-3016(03)00743-0
Gaspar, L.E. and Ding, M. (2008) A Review of Intensity-Modulated Radiation Therapy. Current Oncology Reports, 10, 294-299. http://dx.doi.org/10.1007/s11912-008-0046-3
Yom, S.S., Liao, Z., Liu, H.H., et al. (2007) Initial Evaluation of Treatment-Related Pneumonitis in Advanced-Stage Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 68, 94-102. http://dx.doi.org/10.1016/j.ijrobp.2006.12.031
Sura, S., Gupta, V., Yorke, E., et al. (2008) Intensity-Modulated Radiation Therapy (IMRT) for Inoperable Non-Small Cell Lung Cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) Experience. Radiotherapy and Oncology, 87, 17-23. http://dx.doi.org/10.1016/j.radonc.2008.02.005
Fletcher, G.H. (1973) Clinical Dose-Response Curves of Human Malignant Epithelial Tumours. British Journal of Radiology, 46, 1-12. http://dx.doi.org/10.1259/0007-1285-46-541-1
Chang, A.J. and Bradley, J.D. (2010) Clinical Perspectives on Dose Escalation for Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 11, 299-302. http://dx.doi.org/10.3816/CLC.2010.n.037
Bradley, J., Paulus, R., Komaki, R., et al. (2015) Standard-Dose versus High-Dose Conformal Radiotherapy with Concurrent and Consolidation Carboplatin plus Paclitaxel with or without Cetuximab for Patients with Stage IIIA or IIIB Non-Small-Cell Lung Cancer (RTOG 0617): A Randomised, Two-by-Two Factorial Phase 3 Study. The Lancet Oncology, 16, 187-199. http://dx.doi.org/10.1016/S1470-2045(14)71207-0
Machtay, M., Bae, K., Movsas, B., Paulus, R., Gore, E.M., Komaki, R., et al. (2012) Higher Biologically Effective Dose of Radiotherapy Is Associated with Improved Outcomes for Locally Advanced Non-Small Cell Lung Carcinoma Treated with Chemoradiation: An Analysis of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology, Biology, Physics, 82, 425-434. http://dx.doi.org/10.1016/j.ijrobp.2010.09.004
Kong, F.-M., Haken, R.K.T., Schipper, M.J., Sullivan, M.A., Chen, M., Lopez, C., et al. (2005) High-Dose Radiation Improved Local Tumor Control and Overall Survival in Patients with Inoperable/Unresectable Non-Small-Cell Lung Cancer: Long-Term Results of a Radiation Dose Escalation Study. International Journal of Radiation Oncology, Biology, Physics, 63, 324-333. http://dx.doi.org/10.1016/j.ijrobp.2005.02.010
Zhang, P., Hugo, G.D. and Yan, D. (2008) Planning Study Comparison of Real-Time Target Tracking and Four-Dimensional Inverse Planning for Managing Patient Respiratory Motion. International Journal of Radiation Oncology, Biology, Physics, 72, 1221-1227. http://dx.doi.org/10.1016/j.ijrobp.2008.07.025
Guckenberger, M., Wilbert, J., Richter, A., Baier, K. and Flentje, M. (2011) Potential of Adaptive Radiotherapy to Escalate the Radiation Dose in Combined Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 79, 901-908. http://dx.doi.org/10.1016/j.ijrobp.2010.04.050
Liao, Z.X., Komaki, R., Thames, H.D., Liu, H.H., Tucker, S.L., Mohan, R., et al. (2010) Influence of Technologic Advances on Outcomes in Patients with Unresectable, Locally Advanced Non-Small-Cell Lung Cancer Receiving Concomitant Chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics, 76, 775-781. http://dx.doi.org/10.1016/j.ijrobp.2009.02.032
Guckenberger, M., Kavanagh, A. and Partridge, M. (2012) Combining Advanced Radiotherapy Technologies to Maximize Safety and Tumor Control Probability in Stage III Non-Small Cell Lung Cancer. Strahlentherapie und Onkologie, 188, 894-900. http://dx.doi.org/10.1007/s00066-012-0161-9
Shirvani, S.M., Jiang, J., Gomez, D.R., Chang, J.Y., Buchholz, T.A. and Smith, B.D. (2013) Intensity Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in the United States: Predictors of Use and Association with Toxicities. Lung Cancer, 82, 252-259. http://dx.doi.org/10.1016/j.lungcan.2013.08.015
Wang, S.L., Liao, Z.X., Wei, X., Liu, H.H., Tucker, S.L., Hu, C.-S., et al. (2006) Analysis of Clinical and Dosimetric Factors Associated with Treatment-Related Pneumonitis (TRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC) Treated with Concurrent Chemotherapy and Three-Dimensional Conformal Radiotherapy (3D-CRT). International Journal of Radiation Oncology, Biology, Physics, 66, 1399-1407. http://dx.doi.org/10.1016/j.ijrobp.2006.07.1337
Hall, E.J. (2006) Intensity-Modulated Radiation Therapy, Protons, and the Risk of Second Cancers. International Journal of Radiation Oncology, Biology, Physics, 65, 1-7. http://dx.doi.org/10.1016/j.ijrobp.2006.01.027
Murshed, H., Liu, H.H., Liao, Z.X., Barker, J.L., Wang, X.C., Tucker, S.L., et al. (2004) Dose and Volume Reduction for Normal Lung Using Intensity-Modulated Radiotherapy for Advanced-Stage Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 58, 1258-1267. http://dx.doi.org/10.1016/j.ijrobp.2003.09.086
Liu, H.H., Wang, X.C., Dong, L., Wu, Q.W., Liao, Z.X., Stevens, C.W., et al. (2004) Feasibility of Sparing Lung and Other Thoracic Structures with Intensity-Modulated Radiotherapy for Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 58, 1268-1279. http://dx.doi.org/10.1016/j.ijrobp.2003.09.085
Jiang, Z.-Q., Yang, K.Y., Komaki, R., Wei, X., Tucker, S.L., Zhuang, Y., et al. (2012) Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience. International Journal of Radiation Oncology, Biology, Physics, 83, 332-339. http://dx.doi.org/10.1016/j.ijrobp.2011.06.1963
Shi, A.H., Zhu, G.Y., Wu, H., Yu, R., Li, F.H. and Xu, B. (2010) Analysis of Clinical and Dosimetric Factors Associated with Severe Acute Radiation Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. Radiation Oncology, 5, 35. http://dx.doi.org/10.1186/1748-717x-5-35
Govaert, S.L.A., Troost, E.G.C., Schuurbiers, O.C.J., de Geus-Oei, L.-F., Termeer, A., Span, P.N. and Bussink, J. (2012) Treatment Outcome and Toxicity of Intensity-Modulated (Chemo) Radiotherapy in Stage III Non-Small Cell Lung Cancer Patients. Radiation Oncology, 7, 150. http://dx.doi.org/10.1186/1748-717x-7-150
Marks, L.B., Bentzen, S.M., Deasy, J.O., Kong, F.-M., Bradley, J.D., Vogelius, I.S., et al. (2010) Radiation Dose-Volume Effects in the Lung. International Journal of Radiation Oncology, Biology, Physics, 76, S70-S76. http://dx.doi.org/10.1016/j.ijrobp.2009.06.091
Werner-Wasik, M., Yorke, E., Deasy, J.O., Nam, J. and Marks, L.B. (2010) Radiation Dose-Volume Effects in the Esophagus. International Journal of Radiation Oncology, Biology, Physics, 76, S86-S93. http://dx.doi.org/10.1016/j.ijrobp.2009.05.070
Bradley, J.D., Deasy, J.O., Bentzen, S.M. and El Naqa, I. (2004) Dosimetric Correlates for Acute Esophagitis in Patients Treated with Radiotherapy for Lung Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 58, 1106-1113. http://dx.doi.org/10.1016/j.ijrobp.2003.09.080
Maguire, P.D., Sibley, G.S., Zhou, S.-M., Jamieson, T.A., Light, K.L. and Antoine, P.A. (1999) Clinical and Dosimetric Predictors of Radiation-Induced Esophageal Toxicity. International Journal of Radiation Oncology, Biology, Physics, 45, 97-103. http://dx.doi.org/10.1016/S0360-3016(99)00163-7
Singh, A.K., Lockett, M.A. and Bradley, J.D. (2003) Predictors of Radiation-Induced Esophageal Toxicity in Patients with Non-Small-Cell Lung Cancer Treated with Three-Dimensional Conformal Radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 55, 337-341. http://dx.doi.org/10.1016/S0360-3016(02)03937-8
Jensen, A.D., Munter, M.W., Bischoff, H.G., Haselmann, R., Haberkorn, U., Huber, P.E., et al. (2011) Combined Treatment of Nonsmall Cell Lung Cancer NSCLC Stage III with Intensity-Modulated RT Radiotherapy and Cetuximab: The NEAR Trial. Cancer, 117, 2986-2994. http://dx.doi.org/10.1002/cncr.25888
Uyterlinde, W., Chen, C., Kwint, M., de Bois, J., Vincent, A., Sonke, J.-J., et al. (2013) Prognostic Parameters for Acute Esophagus Toxicity in Intensity Modulated Radiotherapy and Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 107, 392-397. http://dx.doi.org/10.1016/j.radonc.2013.04.012
Kwint, M., Uyterlinde, W., Nijkamp, J., Chen, C., de Bois, J., Sonke, J.-J., et al. (2012) Acute Esophagus Toxicity in Lung Cancer Patients after Intensity Modulated Radiation Therapy and Concurrent Chemotherapy. International Journal of Radiation Oncology, Biology, Physics, 84, 223-228. http://dx.doi.org/10.1016/j.ijrobp.2012.03.027
Wurstbauer, K., Deutschmann, H., Dagn, K., Kopp, P., Zehentmayr, F., Lamprecht, B., et al. (2013) DART-Bid (Dose-Differentiated Accelerated Radiation Therapy, 1.8 Gy Twice Daily)—A Novel Approach for Non-Resected NSCLC: Final Results of a Prospective Study, Correlating Radiation Dose to Tumor Volume. Radiation Oncology, 8, 49. http://dx.doi.org/10.1186/1748-717x-8-49
van Elmpt, W., De Ruysscher, D., van der Salm, A., Lakeman, A., van der Stoep, J., Emans, D., et al. (2012) The PET-Boost Randomised Phase II Dose-Escalation Trial in Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 104, 67-71. http://dx.doi.org/10.1016/j.radonc.2012.03.005